Time to Invest in the Future: Assessing the Cost-Effectiveness of Empagliflozin in Diabetic Kidney Disease

Am J Kidney Dis. 2022 Jun;79(6):780-782. doi: 10.1053/j.ajkd.2021.11.003. Epub 2022 Feb 1.

¹ Department of Medicine, Division of Nephrology, Keck School of Medicine of the University of Southern California, Los Angeles, California.
² Department of Medicine, Los Angeles County+USC Medical Center, Los Angeles, California.
³ Department of Medicine, Division of Nephrology, Keck School of Medicine of the University of Southern California, Los Angeles, California; The Leonard D. Schaeffer Center for Health Policy & Economics, University of Southern California, Los Angeles, California; Sol Price School of Public Policy, University of Southern California, Los Angeles, California. Electronic address: [email protected].

No abstract available

Publication types